Summary The live-attenuated oral poliovirus vaccine (OPV or Sabin vaccine) replicates in gut-associated tissues, eliciting mucosa and systemic immunity. OPV protects from disease and limits poliovirus spread. Accordingly, vaccination with OPV is the primary strategy used to end the circulation of all polioviruses. However, the ability of OPV to regain replication fitness and establish new epidemics represents a significant risk of polio re-emergence should immunization cease. Here, we report the development of a poliovirus type 2 vaccine strain (nOPV2) that is genetically more stable and less likely to regain virulence than the original Sabin2 strain. We introduced modifications within at the 5′ untranslated region of the Sabin2 genome to stabilize attenuation determinants, 2C coding region to prevent recombination, and 3D polymerase to limit viral adaptability. Prior work established that nOPV2 is immunogenic in preclinical and clinical studies, and thus may enable complete poliovirus eradication. Graphical Abstract Highlights • The Sabin vaccine protects from poliomyelitis but can regain neurovirulence • Specific modifications into the Sabin2 genome increase its genetic stability • Slowing down Sabin2 virus evolution prevents reversion and leads to a safer vaccine • The new strain (nOPV2) is safe and immunogenic in preclinical and clinical studies The live-attenuated oral poliovirus vaccine (OPV; Sabin vaccine) can revert to neurovirulent variants, causing safety concerns. Yeh et al. engineer a poliovirus vaccine strain (nOPV2) that preserves the antigenic and immunogenic characteristics of Sabin2 while stabilizing determinants of attenuation and reducing evolvability. nOPV2 is safe and immunogenic in preclinical studies.
【저자키워드】 live-attenuated vaccine, Poliovirus, poliovirus eradication, OPV2, Sabin 2p,